Menu Menu

Best evidence
supporting best care

Supporting Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines

Please note:

As of 31 July 2023, the National Clinical Evidence Taskforce is no longer funded. The COVID-19 and MPX guidelines are still accessible online, but are not currently being updated.

For more information and the latest developments in Australian living evidence visit

The National Clinical Evidence Taskforce is a multi-disciplinary collaboration of 35 member organisations – Australia’s medical colleges and peak health organisations – who share a commitment to provide national evidence-based treatment guidelines for urgent and emerging diseases.

This pioneering alliance established the world’s first ‘living guidelines’ for the care of people with COVID-19 and MPX.

Funding has now been discontinued for the National Clinical Evidence Taskforce and the COVID-19 guidelines as of 30 June 2023.

These guidelines are no longer continually updated but will remain online until the guidance becomes inaccurate and/or no longer reflects the evidence or recommended practice. 

We congratulate and thank our 35 member organisations together with our 250+ clinical and consumer contributors for their extraordinary collaborative efforts over the last three years to develop these guidelines. You can find more information on NCET’s achievements at

We also acknowledge the generosity of our funders without whom this critical work would not have been possible.

Living factsheets

Evidence summaries for relevant diseases in Australia

Do you have a clinical question?

Your views help us to identify and prioritise questions to include in the living guideline.

envelope iconSubscribe here to receive regular updates from the Taskforce


Please enter your email, so we can follow up with you.


Suggest a new topic or clinical question. Please note that our living guideline aims to

“Provide specific, patient-focused recommendations for the clinical care of people with suspected or confirmed COVID-19, where care for this patient group differs from usual care provided to patients with similar clinical conditions (pneumonia, severe acute respiratory distress, etc.)”.

*The following topics for COVID-19 are currently included:

• Definition of disease severity
• Monitoring and markers of clinical deterioration
• Drug treatments (e.g. antimalarials)
• Chemoprophylaxis
• Respiratory support in adults
• Respiratory support in neonates, children and adolescents
• Venous thromboembolism (VTE) prophylaxis
• Therapies for existing indications in patients with COVID-19
• Care of people after COVID-19
• Timing of surgery following COVID-19 infection
• Pregnancy and perinatal care
• Child and adolescent care

*The following topics for MPX are currently included:

• Disease severity and risk of severe disease
• Drug treatments
• Supportive care
• Pregnancy and perinatal care
• Paediatric and adolescent care


Please enter your email to receive our regular updates.

and funders